We are live on ! Find out more
KYTX icon

Kyverna Therapeutics

99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

135% more capital invested

Capital invested by funds: $136M → $321M (+$184M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

32% more funds holding

Funds holding: 7599 (+24)

25.45% more ownership

Funds ownership: 52.48%77.93% (+25%)

19% less call options, than puts

Call options by funds: $967K | Put options by funds: $1.19M

Holders
99
Holders Change
+24
Holders Change %
+32%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
36
Increased
29
Reduced
21
Closed
9
Calls
$967K
Puts
$1.19M
Net Calls
-$227K
Net Calls Change
-$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
51
VOYA Investment Management
Georgia
$641K +$506K +68,140 New
Qube Research & Technologies (QRT)
52
Qube Research & Technologies (QRT)
United Kingdom
$598K +$200K +26,925 +73%
ACM
53
ADAR1 Capital Management
Texas
$540K +$426K +57,428 New
QC
54
Quadrature Capital
United Kingdom
$539K +$426K +57,369 New
NCNMGF
55
Nano-Cap New Millennium Growth Fund
New York
$503K +$397K +53,500 New
Northern Trust
56
Northern Trust
Illinois
$485K -$787 -106 -0.2%
Two Sigma Advisers
57
Two Sigma Advisers
New York
$464K -$237K -31,900 -39%
American Century Companies
58
American Century Companies
Missouri
$436K +$105K +14,162 +44%
OAC
59
OMERS Administration Corp
Ontario, Canada
$327K +$258K +34,800 New
Point72 Asset Management
60
Point72 Asset Management
Connecticut
$303K +$37.2K +5,008 +18%
JFG
61
Jefferies Financial Group
New York
$301K +$117K +15,701 +96%
SSA
62
Schonfeld Strategic Advisors
New York
$271K +$214K +28,872 New
Bank of America
63
Bank of America
North Carolina
$270K -$269K -36,255 -56%
ACM
64
ACT Capital Management
Pennsylvania
$236K +$186K +25,100 New
Raymond James Financial
65
Raymond James Financial
Florida
$236K +$186K +25,082 New
XT
66
XTX Topco
Cayman Islands
$219K -$192K -25,825 -53%
DekaBank Deutsche Girozentrale
67
DekaBank Deutsche Girozentrale
Germany
$197K
Federated Hermes
68
Federated Hermes
Pennsylvania
$195K +$41.2K +5,547 +37%
VPIM
69
Vanguard Personalized Indexing Management
California
$179K +$1.15K +155 +0.8%
CC
70
Caxton Corporation
New Jersey
$176K -$31.2K -4,208 -18%
CIM
71
Cambria Investment Management
California
$169K +$133K +17,935 New
A
72
AlphaQuest
New York
$154K +$121K +16,343 New
EI
73
Ethic Inc
New York
$119K -$20.4K -2,744 -18%
PWA
74
Phoenix Wealth Advisors
North Carolina
$116K +$13.4K +1,800 +17%
Citigroup
75
Citigroup
New York
$116K +$66.7K +8,978 +271%

KYTX Hedge Fund Activity: Q4 2025 in Review

99 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.

  • 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
  • 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
  • The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
  • The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2025.